SEC Filing Summary: Obalon Therapeutics, Inc. (OBLN)
Business Context and Reporting Period
This Form 8-K was filed on June 19, 2020, by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc., as noted in the request metadata). The filing serves to report the Company's financial results for the three months ended March 31, 2020. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Carlsbad, California.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is not included in the source text provided.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the reporting of results for the quarter ended March 31, 2020.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated June 19, 2020), as these are not present in the 8-K text.
- Confirm the Company's name is Obalon Therapeutics, Inc. (OBLN), distinct from Vyome Holdings, Inc.
- Review the full press release for any operational updates or clinical trial progress associated with the Q1 2020 results.
- Check subsequent filings for any updates on liquidity or capital raising efforts following the March 31, 2020 period.